Flt3 ligand enhances the immunogenicity of a gag-based HIV-1 vaccine

Vladimir M. Pisarev, Prahlad Parajuli, R Lee Mosley, Jennifer Sublet, Linda Kelsey, Prem S. Sarin, Daniel H. Zimmerman, M. Douglas Winship, James E Talmadge

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Liposomes and Flt3 ligand (Flt3L), a ligand for the fms-like tyrosine kinase receptor Flt3/ FLK2, can augment the immune response to an HIV peptide vaccine. The HGP-30 peptide used in these studies is a synthetic peptide that corresponds to a highly conserved region of HIV-1 p17 gag (amino acids 86-115). Mice were immunized with HGP-30 or HGP-30 conjugated to keyhole limpet hemocyanin (KLH) and delayed-type hypersensitivity (DTH) responses, antibody (IgG) amount and antigen-specific proliferative responses by spleen cells were used to monitor the immune response. Daily injections of Flt3L prior to HGP-30 administration enhanced significantly an antigen-specific lymphocyte proliferation response when compared with Flt3L, HGP-30 alone or HGP-30 containing liposomes. Intravenous administration of HGP-30 was superior to intramuscular (i.m.) immunization for the induction of DTH responses. The HGP-30/KLH containing liposomes enhanced both DTH and antibody responses, while liposomes containing HGP-30 peptide elicited only T cell responses. In these studies, either Flt3L or liposomes increased DTH responses compared with the i.m. injection of the HGP-30 vaccine alone. Copyright (C) 2000 International Society for Immunopharmacology. Published by Elsevier Science Ltd.

Original languageEnglish (US)
Pages (from-to)865-876
Number of pages12
JournalInternational Journal of Immunopharmacology
Volume22
Issue number11
DOIs
StatePublished - Nov 20 2000

Fingerprint

AIDS Vaccines
Liposomes
Delayed Hypersensitivity
HIV-1
Peptides
Antibody Formation
Vascular Endothelial Growth Factor Receptor-1
Antigens
Subunit Vaccines
Intramuscular Injections
Receptor Protein-Tyrosine Kinases
Intravenous Administration
Immunization
Vaccines
Spleen
Immunoglobulin G
flt3 ligand protein
Lymphocytes
Ligands
T-Lymphocytes

Keywords

  • Flt3 ligand
  • HGP-30 peptide
  • HIV-1 p17 gag

ASJC Scopus subject areas

  • Immunology
  • Pharmacology

Cite this

Flt3 ligand enhances the immunogenicity of a gag-based HIV-1 vaccine. / Pisarev, Vladimir M.; Parajuli, Prahlad; Mosley, R Lee; Sublet, Jennifer; Kelsey, Linda; Sarin, Prem S.; Zimmerman, Daniel H.; Winship, M. Douglas; Talmadge, James E.

In: International Journal of Immunopharmacology, Vol. 22, No. 11, 20.11.2000, p. 865-876.

Research output: Contribution to journalArticle

Pisarev, VM, Parajuli, P, Mosley, RL, Sublet, J, Kelsey, L, Sarin, PS, Zimmerman, DH, Winship, MD & Talmadge, JE 2000, 'Flt3 ligand enhances the immunogenicity of a gag-based HIV-1 vaccine', International Journal of Immunopharmacology, vol. 22, no. 11, pp. 865-876. https://doi.org/10.1016/S0192-0561(00)00048-5
Pisarev, Vladimir M. ; Parajuli, Prahlad ; Mosley, R Lee ; Sublet, Jennifer ; Kelsey, Linda ; Sarin, Prem S. ; Zimmerman, Daniel H. ; Winship, M. Douglas ; Talmadge, James E. / Flt3 ligand enhances the immunogenicity of a gag-based HIV-1 vaccine. In: International Journal of Immunopharmacology. 2000 ; Vol. 22, No. 11. pp. 865-876.
@article{0f3a060ddd7d4c7f9b4fd750aa9e3c88,
title = "Flt3 ligand enhances the immunogenicity of a gag-based HIV-1 vaccine",
abstract = "Liposomes and Flt3 ligand (Flt3L), a ligand for the fms-like tyrosine kinase receptor Flt3/ FLK2, can augment the immune response to an HIV peptide vaccine. The HGP-30 peptide used in these studies is a synthetic peptide that corresponds to a highly conserved region of HIV-1 p17 gag (amino acids 86-115). Mice were immunized with HGP-30 or HGP-30 conjugated to keyhole limpet hemocyanin (KLH) and delayed-type hypersensitivity (DTH) responses, antibody (IgG) amount and antigen-specific proliferative responses by spleen cells were used to monitor the immune response. Daily injections of Flt3L prior to HGP-30 administration enhanced significantly an antigen-specific lymphocyte proliferation response when compared with Flt3L, HGP-30 alone or HGP-30 containing liposomes. Intravenous administration of HGP-30 was superior to intramuscular (i.m.) immunization for the induction of DTH responses. The HGP-30/KLH containing liposomes enhanced both DTH and antibody responses, while liposomes containing HGP-30 peptide elicited only T cell responses. In these studies, either Flt3L or liposomes increased DTH responses compared with the i.m. injection of the HGP-30 vaccine alone. Copyright (C) 2000 International Society for Immunopharmacology. Published by Elsevier Science Ltd.",
keywords = "Flt3 ligand, HGP-30 peptide, HIV-1 p17 gag",
author = "Pisarev, {Vladimir M.} and Prahlad Parajuli and Mosley, {R Lee} and Jennifer Sublet and Linda Kelsey and Sarin, {Prem S.} and Zimmerman, {Daniel H.} and Winship, {M. Douglas} and Talmadge, {James E}",
year = "2000",
month = "11",
day = "20",
doi = "10.1016/S0192-0561(00)00048-5",
language = "English (US)",
volume = "22",
pages = "865--876",
journal = "International Immunopharmacology",
issn = "1567-5769",
publisher = "Elsevier",
number = "11",

}

TY - JOUR

T1 - Flt3 ligand enhances the immunogenicity of a gag-based HIV-1 vaccine

AU - Pisarev, Vladimir M.

AU - Parajuli, Prahlad

AU - Mosley, R Lee

AU - Sublet, Jennifer

AU - Kelsey, Linda

AU - Sarin, Prem S.

AU - Zimmerman, Daniel H.

AU - Winship, M. Douglas

AU - Talmadge, James E

PY - 2000/11/20

Y1 - 2000/11/20

N2 - Liposomes and Flt3 ligand (Flt3L), a ligand for the fms-like tyrosine kinase receptor Flt3/ FLK2, can augment the immune response to an HIV peptide vaccine. The HGP-30 peptide used in these studies is a synthetic peptide that corresponds to a highly conserved region of HIV-1 p17 gag (amino acids 86-115). Mice were immunized with HGP-30 or HGP-30 conjugated to keyhole limpet hemocyanin (KLH) and delayed-type hypersensitivity (DTH) responses, antibody (IgG) amount and antigen-specific proliferative responses by spleen cells were used to monitor the immune response. Daily injections of Flt3L prior to HGP-30 administration enhanced significantly an antigen-specific lymphocyte proliferation response when compared with Flt3L, HGP-30 alone or HGP-30 containing liposomes. Intravenous administration of HGP-30 was superior to intramuscular (i.m.) immunization for the induction of DTH responses. The HGP-30/KLH containing liposomes enhanced both DTH and antibody responses, while liposomes containing HGP-30 peptide elicited only T cell responses. In these studies, either Flt3L or liposomes increased DTH responses compared with the i.m. injection of the HGP-30 vaccine alone. Copyright (C) 2000 International Society for Immunopharmacology. Published by Elsevier Science Ltd.

AB - Liposomes and Flt3 ligand (Flt3L), a ligand for the fms-like tyrosine kinase receptor Flt3/ FLK2, can augment the immune response to an HIV peptide vaccine. The HGP-30 peptide used in these studies is a synthetic peptide that corresponds to a highly conserved region of HIV-1 p17 gag (amino acids 86-115). Mice were immunized with HGP-30 or HGP-30 conjugated to keyhole limpet hemocyanin (KLH) and delayed-type hypersensitivity (DTH) responses, antibody (IgG) amount and antigen-specific proliferative responses by spleen cells were used to monitor the immune response. Daily injections of Flt3L prior to HGP-30 administration enhanced significantly an antigen-specific lymphocyte proliferation response when compared with Flt3L, HGP-30 alone or HGP-30 containing liposomes. Intravenous administration of HGP-30 was superior to intramuscular (i.m.) immunization for the induction of DTH responses. The HGP-30/KLH containing liposomes enhanced both DTH and antibody responses, while liposomes containing HGP-30 peptide elicited only T cell responses. In these studies, either Flt3L or liposomes increased DTH responses compared with the i.m. injection of the HGP-30 vaccine alone. Copyright (C) 2000 International Society for Immunopharmacology. Published by Elsevier Science Ltd.

KW - Flt3 ligand

KW - HGP-30 peptide

KW - HIV-1 p17 gag

UR - http://www.scopus.com/inward/record.url?scp=0033772895&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033772895&partnerID=8YFLogxK

U2 - 10.1016/S0192-0561(00)00048-5

DO - 10.1016/S0192-0561(00)00048-5

M3 - Article

VL - 22

SP - 865

EP - 876

JO - International Immunopharmacology

JF - International Immunopharmacology

SN - 1567-5769

IS - 11

ER -